Skip to content
How Biotech M&A is Redefining the Strategic Landscape episode artwork

Jun 23, 2023 25 min

How Biotech M&A is Redefining the Strategic Landscape

from Pathfinders in Biopharma

Given current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets Analysts Dr. Brian Abrahams, Dr. Luca Issi and Dr. Gregory Renza.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

How Biotech M&A is Redefining the Strategic Landscape

0:00 25:53

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Pathfinders in Biopharma?

This episode is 25 minutes long.

When was this Pathfinders in Biopharma episode published?

This episode was published on June 23, 2023.

Can I download this Pathfinders in Biopharma episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.